{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:43:41Z","timestamp":1793058221582,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphocytes play a key role in the pathogenesis of inflammatory bowel disease (IBD) and are widely explored as promising prognostic indicators. We aimed to outline the existing evidences on the capability of lymphocyte subpopulations to predict disease progression and treatment response in patients with IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The protocol for this review was registered in PROSPERO (registration ID: CRD 42022364126). Systematic retrieval was conducted using PubMed, Embase, and Web of Science databases. Original articles on the prognostic value of lymphocyte subsets in IBD published up to April 8, 2023 were eligible for inclusion. The Newcastle\u2013Ottawa Scale was used to evaluate the risk of bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty studies were ultimately included: eight evaluated the prediction of disease progression and 12 focused on the prediction of treatment response. According to the Newcastle\u2013Ottawa Scale, three studies were of high quality, 16 were of moderate quality, and only one was of low quality. T-cell subpopulations, including CD4<jats:sup>+<\/jats:sup> T cells, CD8<jats:sup>+<\/jats:sup> T cells, and \u03b3\u03b4 T cells, are revealed to have prognostic capacity. Transmembrane tumor necrosis factor \u03b1-bearing lymphocytes, CD4<jats:sup>+<\/jats:sup> T cells, CD8<jats:sup>+<\/jats:sup> T cells, and Plasma cells are found to have the potential to predict the response to anti-TNF\u03b1 agents. In contrast memory T cells, CD4<jats:sup>+<\/jats:sup> T cells, and na\u00efve B cells may predict the response to vedolizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This systematic review identified several potential lymphocyte subset-related predictors. If verified in large cohort prospective studies, these findings could aid clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42022364126.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1403420","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:46:25Z","timestamp":1724129185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Rirong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312135","article-title":"Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease","volume":"67","author":"Imhann","year":"2018","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn's disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb4432","article-title":"Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses","volume":"5","author":"Boland","year":"2020","journal-title":"Sci Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.043","article-title":"Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease","volume":"128","author":"Maul","year":"2005","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636435","article-title":"Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells","volume":"37","author":"Wang","year":"2007","journal-title":"Eur J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.09.046","article-title":"Treat to target: the role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis","volume":"19","author":"Gupta","year":"2021","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2011.603157","article-title":"Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells","volume":"46","author":"Dige","year":"2011","journal-title":"Scandinavian J Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/2050640613502962","article-title":"CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis","volume":"1","author":"Magnusson","year":"2013","journal-title":"United Eur Gastroenterol J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centered meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2021.04.011","article-title":"MIN score predicts primary response to infliximab\/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases","volume":"113","author":"Shi","year":"2021","journal-title":"Genomics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21271","article-title":"Peripheral regulatory T cells and serum transforming growth factor-\u03b2: relationship with clinical response to infliximab in Crohn's disease","volume":"16","author":"Di Sabatino","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000509","article-title":"Restoration of Foxp3+ Regulatory T-cell subsets and Foxp3- type 1 regulatory-like T cells in inflammatory bowel diseases during anti-tumor necrosis factor therapy","volume":"21","author":"Li","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00005-020-00575-5","article-title":"Specific T-cell subsets can predict the efficacy of anti-TNF treatment in inflammatory bowel diseases","volume":"68","author":"Dulic","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.44","article-title":"Transmembrane TNF-\u03b1 Density, but not Soluble TNF-\u03b1 Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease","volume":"8","author":"Amini Kadijani","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007247","article-title":"Decreased CD8+CD28+\/CD8+CD28- T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease","volume":"96","author":"Dai","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv211","article-title":"Enrichment of circulating and mucosal cytotoxic CD8+ T cells is associated with postoperative endoscopic recurrence in patients with crohn's disease","volume":"10","author":"Boschetti","year":"2016","journal-title":"J Crohn's colitis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2019.11.003","article-title":"Gammadelta T cells as a predictor of surgical relapse of Crohn's disease","volume":"44","author":"Andreu-Ballester","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12592","article-title":"Imbalances of CD4(+) T-cell subgroups in Crohn's disease and their relationship with disease activity and prognosis","volume":"29","author":"Chao","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course","volume":"12","author":"Smids","year":"2018","journal-title":"J Crohn's Colitis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864353","article-title":"Relationships of circulating CD4(+) T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease","volume":"13","author":"Duclaux-Loras","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317878","article-title":"T cell clonal expansions in ileal Crohn's disease are associated with smoking behavior and postoperative recurrence","volume":"68","author":"Allez","year":"2019","journal-title":"Gut. Nov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000061","article-title":"Weak cytotoxic T cells activation predicts low-grade dysplasia persistence in ulcerative colitis","volume":"10","author":"Kotsafti","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression levels of 4 genes in colon tissue might be used to predict which patients will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases","volume":"18","author":"Verstockt","year":"2020","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa035","article-title":"Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases","volume":"14","author":"Coletta","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.837294","article-title":"Memory T cell subpopulations as early predictors of remission to vedolizumab in ulcerative colitis","volume":"9","author":"Gonzalez-Vivo","year":"2022","journal-title":"Front Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.077","article-title":"The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease","volume":"162","author":"Lamb","year":"2022","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05002.x","article-title":"Review article: the natural history of postoperative Crohn's disease recurrence","volume":"35","author":"Buisson","year":"2012","journal-title":"Alimentary Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: A systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310022","article-title":"Differential effects of \u03b14\u03b27 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo","volume":"65","author":"Fischer","year":"2016","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatology. Jul"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac100","article-title":"Endoscopic postoperative recurrence in crohn's disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: A real-world multicenter European study","author":"Yanai","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumor necrosis factor \u03b1 Real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Alimentary Pharmacol Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1712","article-title":"Vedolizumab for inflammatory bowel disease: two-year results of the initiative on crohn and colitis (ICC) registry, A nationwide prospective observational cohort study: ICC registry - vedolizumab","volume":"107","author":"Biemans","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.012","article-title":"Interactions between the host innate immune system and microbes in inflammatory bowel disease","volume":"140","author":"Abraham","year":"2011","journal-title":"Gastroenterology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.07.013","article-title":"Understanding inflammatory bowel disease via immunogenetics","volume":"64","author":"de Lange","year":"2015","journal-title":"J Autoimmunity"},{"key":"B58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [Anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/cells8060515","article-title":"Pre-treatment biomarkers of anti-tumor necrosis factor therapy response in Crohn's disease-A systematic review and gene ontology analysis","volume":"8","author":"Gole","year":"2019","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/biomedicines12050952","article-title":"Cytokine profile in predicting the effectiveness of advanced therapy for ulcerative colitis: A narrative review","volume":"12","author":"Kurumi","year":"2024","journal-title":"Biomedicines"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15033","article-title":"Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalized medicine in its infancy","volume":"48","author":"Stevens","year":"2018","journal-title":"Alimentary Pharmacol Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicenter, open-label randomized controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59255","article-title":"Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis","volume":"121","author":"Lee","year":"2011","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.017","article-title":"Transcription and DNA methylation patterns of blood-derived CD8 T cells are associated with age and inflammatory bowel disease but do not predict prognosis","volume":"160","author":"Gasparetto","year":"2021","journal-title":"Gastroenterology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18006","article-title":"Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease","volume":"59","author":"Yiu","year":"2024","journal-title":"Alimentary Pharmacol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1403420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:46:29Z","timestamp":1724129189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1403420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2024.1403420"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1403420","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"1403420"}}